260 related articles for article (PubMed ID: 16411180)
1. Role of P16(INK4a) expression in identifying CIN2 or more severe lesions among HPV-positive patients referred for colposcopy after abnormal cytology.
Carozzi F; Cecchini S; Confortini M; Becattini V; Cariaggi MP; Pontenani G; Sani C; Ciatto S
Cancer; 2006 Apr; 108(2):119-23. PubMed ID: 16411180
[TBL] [Abstract][Full Text] [Related]
2. High-risk human papillomavirus DNA test and p16(INK4a) in the triage of LSIL: a prospective diagnostic study.
Tsoumpou I; Valasoulis G; Founta C; Kyrgiou M; Nasioutziki M; Daponte A; Koliopoulos G; Malamou-Mitsi V; Karakitsos P; Paraskevaidis E
Gynecol Oncol; 2011 Apr; 121(1):49-53. PubMed ID: 21194734
[TBL] [Abstract][Full Text] [Related]
3. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
4. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
5. p16/ki67 and E6/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women.
Giorgi Rossi P; Carozzi F; Ronco G; Allia E; Bisanzi S; Gillio-Tos A; De Marco L; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Barca A; Bonvicini L; Mancuso P; Venturelli F; Benevolo M;
J Natl Cancer Inst; 2021 Mar; 113(3):292-300. PubMed ID: 32745170
[TBL] [Abstract][Full Text] [Related]
6. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
[TBL] [Abstract][Full Text] [Related]
7. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
[TBL] [Abstract][Full Text] [Related]
8. Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.
Clarke MA; Cheung LC; Castle PE; Schiffman M; Tokugawa D; Poitras N; Lorey T; Kinney W; Wentzensen N
JAMA Oncol; 2019 Feb; 5(2):181-186. PubMed ID: 30325982
[TBL] [Abstract][Full Text] [Related]
9. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
10. [Clinical value of p16
Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
[No Abstract] [Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
13. Performance of p16INK4a-cytology, HPV mRNA, and HPV DNA testing to identify high grade cervical dysplasia in women with abnormal screening results.
Reuschenbach M; Clad A; von Knebel Doeberitz C; Wentzensen N; Rahmsdorf J; Schaffrath F; Griesser H; Freudenberg N; von Knebel Doeberitz M
Gynecol Oncol; 2010 Oct; 119(1):98-105. PubMed ID: 20619445
[TBL] [Abstract][Full Text] [Related]
14. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
15. Are adjunctive markers useful in routine cervical cancer screening? Application of p16(INK4a) and HPV-PCR on ThinPrep samples with histological follow-up.
Schledermann D; Andersen BT; Bisgaard K; Dohse M; Ejersbo D; Hoelund B; Horal P; Lindh M; Ryd W
Diagn Cytopathol; 2008 Jul; 36(7):453-9. PubMed ID: 18528890
[TBL] [Abstract][Full Text] [Related]
16. Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study.
Ikenberg H; Bergeron C; Schmidt D; Griesser H; Alameda F; Angeloni C; Bogers J; Dachez R; Denton K; Hariri J; Keller T; von Knebel Doeberitz M; Neumann HH; Puig-Tintore LM; Sideri M; Rehm S; Ridder R;
J Natl Cancer Inst; 2013 Oct; 105(20):1550-7. PubMed ID: 24096620
[TBL] [Abstract][Full Text] [Related]
17. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
18. The triage of low-grade cytological abnormalities by the immunocytological expression of cyclin-dependent kinase inhibitor p16INK4a versus Human Papillomavirus test: a real possibility to predict cervical intraepithelial neoplasia CIN2 or CIN2+.
Stănculescu R; Brătilă E; Bauşic V; Vlădescu T
Rom J Morphol Embryol; 2013; 54(4):1061-5. PubMed ID: 24399002
[TBL] [Abstract][Full Text] [Related]
19. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.
Tsoumpou I; Arbyn M; Kyrgiou M; Wentzensen N; Koliopoulos G; Martin-Hirsch P; Malamou-Mitsi V; Paraskevaidis E
Cancer Treat Rev; 2009 May; 35(3):210-20. PubMed ID: 19261387
[TBL] [Abstract][Full Text] [Related]
20. The predictive value of p16(INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia.
Guo M; Hu L; Baliga M; He Z; Hughson MD
Am J Clin Pathol; 2004 Dec; 122(6):894-901. PubMed ID: 15539381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]